XBI Stock Recent News

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.

The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will determine the direction of small and midcap biotech stocks in the months and quarters ahead. These are highlighted in the paragraphs below about SPDR® S&P Biotech ETF.

Making its debut on 01/31/2006, smart beta exchange traded fund SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

SPDR S&P Biotech ETF offers a buying opportunity after a recent decline and trades close to the 200-day moving average. XBI has a strong long-term track record, providing generous total returns for shareholders. The biotech sector is seeing increased levels of merger and acquisition deals, indicating potential undervaluation in biotech stocks.

Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.

Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. Evidence of improving fundamentals and rising mergers and acquisitions (M&A) activity within the biotechnology space has been underappreciated by investors.

Jared Holz, Mizuho Securities America healthcare equity strategist, joins 'The Exchange' to discuss why he believes we are in the midst of the most pronounced biotech rally in over five years, whether it's too late to get in on the trade, and more.